UNSPSC 51143209: Acamprosate calcium

This classification denotes a neuroprotective agent with the molecular formula 2C5H10NO4S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59375N1D0U, chemically known as 1-propanesulfonic acid, 3-(acetylamino)-, calcium salt (2:1) but more generally known as acamprosate calcium, which bears US NIH Compound Identifier 155434. European Medicines Agency schedules Acamprosate calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00239MIG.

Most nations, for tariff and trade purposes, schedule acamprosate calcium under HS 29241900 and SITC 51471. As of Q4 2014, ACAMPROSATE CALCIUM remains US FDA's Preferred Term for this commodity. Acamprosate calcium bears US NLM identifiers UMLS ID C0592789 and NCI Concept Code C65209. SMILES: CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[CA+2].

UNSPSC 51143209 Acamprosate calcium is a Commodity code tracking pharmaceutical procurement by state and local health agencies, but the recent opportunities block shows a mismatch: Seminole County, Florida posted an IFB for naloxone and drug deactivation systems, not acamprosate calcium. Acamprosate is an oral medication used in alcohol-use-disorder treatment, while naloxone is an opioid antagonist and the deactivation systems are medical disposal equipment. The code appears to show little relevant recent activity aligned with its nominal pharmaceutical scope.

The single identifiable opportunity under this code reflects Seminole County's health department seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023—a date conflict suggesting data inconsistency in the source. Delivery is quarterly to Seminole County Community Health Building in Sanford, Florida, with vendors responsible for shipping costs. The contract carries a two-year initial term with a one-year renewal option, fixed-fee pricing, drug-free workplace and E-Verify compliance requirements, and potential FEMA funding with associated federal environmental and audit obligations. Without additional opportunities in the source block, geographic spread and issuing-body patterns cannot be characterized. Firms evaluating this code should clarify whether state and local procurement systems are tagging acamprosate procurement under this code or whether the naloxone opportunity reflects a classification error.